AIM: To compare attitudes to illness and treatment with self-reported behaviour in predicting inhaler use in asthmatic patients. METHODS: In five practices, 45 patients had their β-2-agonist and steroid inhalers exchanged for Ventolin and Flixotide Accuhalers™. They completed the Illness Perception Questionnaire, the Attitudes to Treatment for Asthma Questionnaire, and a self-report questionnaire at entry, after one month's run-in, and at three months. A nurse counted the number of doses used. Univariate analysis was performed with Accuhaler use over three months as the dependent variable. Independent variables included the questionnaire sub-scales and morbidity. Significant variables were entered into multiple linear regression. RESULTS: The self-report questionnaire explained 40% of the variance of steroid use. The ATAQ relief sub-scale and morbidity explained 29% of the variance of β-2-agonist use. CONCLUSIONS: Steroid inhaler use can be partly predicted by self-reported behaviour and β-2-agonist use by attitudes to inhaler treatment. These findings have implications for patient education.
AIM: To compare attitudes to illness and treatment with self-reported behaviour in predicting inhaler use in asthmatic patients. METHODS: In five practices, 45 patients had their β-2-agonist and steroid inhalers exchanged for Ventolin and Flixotide Accuhalers™. They completed the Illness Perception Questionnaire, the Attitudes to Treatment for Asthma Questionnaire, and a self-report questionnaire at entry, after one month's run-in, and at three months. A nurse counted the number of doses used. Univariate analysis was performed with Accuhaler use over three months as the dependent variable. Independent variables included the questionnaire sub-scales and morbidity. Significant variables were entered into multiple linear regression. RESULTS: The self-report questionnaire explained 40% of the variance of steroid use. The ATAQ relief sub-scale and morbidity explained 29% of the variance of β-2-agonist use. CONCLUSIONS: Steroid inhaler use can be partly predicted by self-reported behaviour and β-2-agonist use by attitudes to inhaler treatment. These findings have implications for patient education.
Authors: Philip Gerretsen; Julia Kim; Parita Shah; Lena Quilty; Thushanthi Balakumar; Fernando Caravaggio; Eric Plitman; Jun Ku Chung; Yusuke Iwata; Bruce G Pollock; Satya Dash; Sanjeev Sockalingam; Ariel Graff-Guerrero Journal: J Clin Hypertens (Greenwich) Date: 2018-03-10 Impact factor: 3.738
Authors: Chen Yan; Yemin Yuan; Dan Zhao; Jie Li; Peipei Fu; Yan Chen; Jie Li; Zhixian Li; Shijun Yang; Wenjuan Li; Zhen Gui; Xiuqing Peng; Chengchao Zhou Journal: Front Public Health Date: 2022-03-16